InMed shares surge 19.51% premarket after completing key pharmacokinetic studies for Alzheimer's candidate INM-901, advancing to human trials.

InMed Pharmaceuticals Inc. surged 19.51% in premarket trading following the announcement that it successfully completed pharmacokinetic studies for its Alzheimer’s candidate INM-901 in large animal models. The results demonstrated favorable bioavailability and no adverse neural or behavioral effects, supporting the advancement to first human clinical trials and a pre-IND meeting with the FDA. These developments reinforce the therapeutic potential of INM-901 for neurodegenerative disorders and underscore regulatory progress.